Published in Pharm Res on October 03, 2007
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines (2010) 1.57
The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun (2008) 0.93
Cytotoxicity of surface-functionalized silicon and germanium nanoparticles: the dominant role of surface charges. Nanoscale (2013) 0.91
In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines. Nano Today (2011) 0.88
Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano (2013) 0.88
Lipopolysaccharide-pretreated plasmacytoid dendritic cells ameliorate experimental chronic kidney disease. Kidney Int (2012) 0.85
A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA. PLoS One (2013) 0.82
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small (2015) 0.80
Revolutionary impact of nanodrug delivery on neuroscience. Curr Neuropharmacol (2012) 0.79
Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation. Bioconjug Chem (2011) 0.79
STAT6 siRNA matrix-loaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells. Biomed Res Int (2013) 0.78
The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization. Hum Vaccin Immunother (2013) 0.77
A polymer/oil based nanovaccine as a single-dose immunization approach. PLoS One (2013) 0.77
Nanoparticulate CpG immunotherapy in RAO-affected horses: phase I and IIa study. J Vet Intern Med (2015) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Non-invasive administration of biodegradable nano-carrier vaccines. Am J Transl Res (2017) 0.75
Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity. Carbohydr Res (2014) 0.75
Multilayered Magnetic Gelatin Membrane Scaffolds. ACS Appl Mater Interfaces (2015) 0.75
Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene. PLoS One (2017) 0.75
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol (2009) 6.97
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature (2009) 5.00
Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell (2013) 3.92
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol (2009) 3.58
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci U S A (2009) 3.05
Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol (2003) 2.87
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest (2009) 2.85
Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity (2013) 2.79
Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol (2003) 2.68
Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut (2010) 2.42
Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity (2013) 2.39
Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol (2004) 2.39
TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity (2008) 2.37
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol (2005) 2.31
Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol (2010) 2.30
Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol (2005) 2.16
Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat Struct Mol Biol (2010) 2.13
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
siRNA and isRNA: two edges of one sword. Mol Ther (2006) 2.02
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res (2011) 1.89
Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J Immunol (2004) 1.85
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell (2013) 1.82
Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol (2008) 1.79
Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol (2003) 1.76
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol (2002) 1.76
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem (2004) 1.61
Approaching the RNA ligand for RIG-I? Immunol Rev (2009) 1.57
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res (2005) 1.49
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (2002) 1.47
PfEMP1-DBL1alpha amino acid motifs in severe disease states of Plasmodium falciparum malaria. Proc Natl Acad Sci U S A (2007) 1.47
SiRNA delivery with exosome nanoparticles. Nat Biotechnol (2011) 1.46
Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res (2003) 1.44
IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol (2004) 1.40
Cellular immunostimulation by CpG-sequence-coated DNA origami structures. ACS Nano (2011) 1.38
Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med Biol (2007) 1.31
Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS (2012) 1.28
Plasmacytoid dendritic cells: the key to CpG. Hum Immunol (2002) 1.28
Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci (2007) 1.27
The chase for the RIG-I ligand--recent advances. Mol Ther (2010) 1.27
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol (2009) 1.25
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
Morphological and immunocytochemical characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing. J Anat (2009) 1.24
T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J Immunol (2006) 1.23
Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol (2008) 1.21
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2003) 1.19
How subvisible particles become invisible-relevance of the refractive index for protein particle analysis. J Pharm Sci (2013) 1.18
Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol (2008) 1.18
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res (2013) 1.17
Microbubbles as ultrasound triggered drug carriers. J Pharm Sci (2009) 1.16
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci (2010) 1.16
Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol (2002) 1.14
RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids. EMBO J (2012) 1.14
The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci (2007) 1.12